Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high costs—often exceeding $1,000 per month—put them out of reach for many Americans whose ...
Please log in, or sign up for a new account and purchase a subscription to continue reading. BEST VALUE! Like never before, the News-Argus delivers real value every ...